References for Part
2 of Over Dose: The Case Against the Drug Companies
54.-58. Cohen, see references 36-39, 42.
59. Mullen WH; Anderson IB; Kim SY; Blanc
PD; Olson KR. Incorrect overdose management advice in the Physicians'
Desk Reference. Annals of Emergency Medicine, 1997; 29(2):255?61.
60. Gebhart, F. Is Standard Dosing to Blame
for Adverse Drug Reactions? Drug Therapy, Jan. 17, 2000;34.
61. Food and Drug Administration. Postmarketing
Safety of Sildenafil Citrate (Viagra). Summary of Reports of Death in
Viagra Users Received from Marketing (Late March) through Mid-November
1998. FDA website: http://www.fda.gov/cder/consumerinfo/viagra/safety3.htm
62. Cauchon, D. FDA Advisors Tied to Industry:
Approval Process Riddled with Conflicts of Interest. USA TODAY, Sept.
25, 2000.
63. Moore et al., op. cit.
64. Dickinson's FDA Review, Sept. 2000,
7:11. Reductions compared times between 1994-95 and 1998-99.
65. Wolfe, S. "FDA Medical Officers
Report Lower Standards Permit Dangerous Drug Approvals." Worst Pills,
Best Pills News, Jan. 1999;5:7-8.
66. Wood AJ. The safety of new medicines:
the importance of asking the right questions [editorial]. JAMA, 1999 May
12, 281(18):1753?4.
67. Ibid.
68. Woosley, R.L., Chen, Y., Freiman, J.P.,
Gillis, R.A. Mechanism of the Cardiotoxic Actions of Terfenadine. JAMA,
1993; 269(12), 1532-6.
69. Moore, TJ. The FDA in Crisis. Boston
Globe, Sun., April 2, 2000.
70. Moore, TJ, Psaty, BM, Furberg, CD,
op. cit.
71. Riva, C. "Consequences of Medical
Error -- 16,000 Swiss Sick from Medicine -- Who Is at Fault? The Pharmaceutical
Industry or the One Who Writes the Prescription? A New Law Will Oblige
Doctors Mention the Side Effects of Medicine." Dimanche, April 2,
2000.
72. Angell, "Is Academic Medicine
for Sale?" op. cit.
73. Weiss, R. Correctly Prescribed Drugs
Take Heavy Toll. Washington Post, Weds., April 15, 1998, A-1, 8.
74. Willman, D. 3 Lawmakers Question FDA
on Diabetes Pill Approval: Letter by House Democrats Asks Why Rezulin
Was Kept on Market Despite Deaths. Issues Go to "Heart of Public's
Confidence." Los Angeles Times, Weds., Dec. 23, 1998: A-22.
75. Sulkowski MS; Thomas DL; Chaisson RE;
Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults
infected with human immunodeficiency virus and the role of hepatitis C
or B virus infection. JAMA, 2000 Jan 5, 283(1):74?80.
76. Neergaard, L (Associated Press). Some
AIDS Patients Are Hit by Disfiguring Fat Deposits: FDA Says Protease Inhibitor
Drugs Are Suspected As a Cause. High Levels of Cholesterol Are Also Reported.
Philadelphia Inquirer, Mon., June 15, 1998: A-2.
77. Wolfe, SM, Editor. Sudden Deaths Reported
with Pimozide (Orap). Worst Pills, Best Pills News, Public Citizen Health
Research Group, Nov., 1999; 5:87.
78. Draganov, P, Durrence, H, Cox, C, Reuben,
A. Alcohol-Acetaminophen Syndrome: Even Moderate Social Drinkers Are at
Risk. Postgraduate Medicine, 2000; 107: 189-195.
79. Psychosis due to abrupt discontinuation
of an oral contraceptive. Primary Psychiatry, Nov. 1999; 6:20.
80. Bynum, R (Associated Press). Antibiotic
Linked to Stomach Disorder in Infants. San Diego Union-Tribune, Fri.,
Dec. 17, 1999: A-21.
81. Roan, S. Study Links Breast Cancer,
Hormone Use. Los Angeles Times, Weds., Jan. 26, 2000: A-1, 15.
82. Associated Press. Maker of Fen-Phen
Paid for Articles: Lawsuit Says Wyeth Hid Dangers Linked to Weight-Loss
Drug. San Diego Union-Tribune, May 25, 1999.
83. Wolfe, SM, Editor. New Adverse Reaction
Warning: Liver Toxicity with Prostate Cancer Drug Flutamide (Eulexin).
Worst Pills, Best Pills News, Public Citizen Health Research Group, Nov.,
1999; 5:88.
84. Food and Drug Administration. "Trovan
Associated with Liver Injury and Death." Revised Labeling Confirmation
to Pfizer, Inc., May 17, 2000:FDA Website.
85. Page, J, Henry, D. Consumption of NSAIDs
and the Development of Congestive Heart Failure in Elderly Patients --
and Unrecognized Public Health Problem. Archives of Internal Medicine,
2000; 160:777-84.
86. de Abajo FJ; Rodriguez LA; Montero
D. Association between selective serotonin reuptake inhibitors and upper
gastrointestinal bleeding: population based case?control study. BMJ, 1999
Oct 23, 319(7217):1106?9.
87. Maugh, TH. Beta-Blockers Linked to
Diabetes in Study. Los Angeles Times, Mon., April 3, 2000: S3.
88. Lagergren J; Bergstrom R; Adami HO;
Nyren O. Association between medications that relax the lower esophageal
sphincter and risk for esophageal adenocarcinoma. Annals of Internal Medicine,
2000 Aug 1, 133(3):165?75.
89. Moore et al., "Time to act on
drug safety," op. cit.
90. Modell JG; Katholi CR; Modell JD; DePalma
RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine,
and sertraline. Clinical Pharmacology and Therapeutics, 1997 Apr, 61(4):476?87.
91. Montejo?Gonzalez AL; Llorca G; Izquierdo
JA; Ledesma A; Bousono M; Calcedo A; et al. SSRI?induced sexual dysfunction:
fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective,
multicenter, and descriptive clinical study of 344 patients. Journal of
Sex and Marital Therapy, 1997 Fall, 23(3):176?94.
92. Hirschfeld RM. Management of sexual
side effects of antidepressant therapy. Journal of Clinical Psychiatry,
1999, 60 Suppl 14:27?30; discussion 31?5.
93. Willman, D. FDA's expedited drug approvals
cost lives. Los Angeles Times, Fri., Dec. 29, 2000.
94. Angell, op. cit.
95. Ibid.
96. Sanson?Fisher RW; Clover K. Compliance
in the treatment of hypertension. A need for action. American Journal
of Hypertension, 1995; 8(10 Pt 2):82S?88S.
97. Feldman R; Bacher M; Campbell N; et
al. Adherence to pharmacologic management of hypertension. Canadian Journal
of Public Health, 1998; 89(5):I16?8.
98. Roberts, W.C. The underused miracle
drugs: the statin drugs are to atherosclerosis what penicillin was to
infectious disease. American Journal of Cardiology, 1996;78:377-8.
99. Avorn J, Monette J, Lacour A, Bohn
RL, Monane M, Mogun H, et al. Persistence of use of lipid?lowering medications:
a cross?national study. JAMA, 1998;279(18):1458?62.
100. Brett KM; Madans JH. Use of postmenopausal
hormone replacement therapy: estimates from a nationally representative
cohort study. American Journal of Epidemiology, 1997 Mar 15, 145(6):536?45.
101. Saver BG; Taylor TR; Woods NF. Use
of hormone replacement therapy in Washington State: is prevention being
put into practice? Journal of Family Practice, 1999 May, 48(5):364?71.
[101A. Schairer C; Lubin J; Troisi R; Sturgeon
S; Brinton L; Hoover R. Menopausal estrogen and estrogen?progestin replacement
therapy and breast cancer risk. JAMA, 2000 Jan 26, 283(4):485?91.]
102. Wood, op. cit.
103. Willman, D. The Rise and Fall of the
Killer Drug Rezulin: People were dying as specialists waged war against
their FDA superiors. Patient safety was at stake in the scramble to keep
a `fast-track' pill on the U.S. market." Los Angeles Times, Sun.,
June 4, 2000: A-1,16-18.
104. Willman, D. FDA Minimized Issue of
Lotronex'S Safety: Times Study Finds Officials Sided with Drug Maker or
Regulatory Concerns; Agency Reevaluation Underway. Los Angeles Times,
Thurs., Nov. 2, 2000:A-1,15.
105. Willman, D. Blood Pressure Pill OKed
Before Study Ended. Los Angeles Times, Weds., Jan. 10, 2001.
Return to Over Dose: The Case Against
the Drug Companies: Part 1, Part
2
